Skip to main content

The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published. 

 

Acute Lymphoblastic Leukemia (ALL) in Adults

Acute Lymphoblastic Leukemia (ALL) in Children and Teens

 The ALL Guide: Information for Patients and Caregivers

  • In November 2025, the Food and Drug Administration (FDA) expanded the indication of Revumenib (Revuforj®) to include the treatment of adults and children 1 year and older with acute myeloid leukemia with a nucleophosmin 1 (NPM1) mutation whose disease has come back or has not improved after previous treatment(s) and who have no other satisfactory treatment options.
  • In November 2024, the Food and Drug Administration (FDA) approved revumenib (Revuforj®) for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
  • In November 2024, the Food and Drug Administration (FDA) approved obecabtagene autoleucel (Aucatzyl®) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
  • In June 2024, the Food and Drug Administration (FDA) expanded the indication of blinatumomab (Blincyto®) to include the treatment of adult and pediatric patients one month and older with:
    • CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.  
    • Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).  
    • CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.
  • As of June 2024, Erwinaze® (asparaginase erwinia chrysanthemi) has been discontinued. Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) is available as a treatment option.

 

Acute Myeloid Leukemia (AML) in Adults: In Detail

Acute Myeloid Leukemia in Children and Teens: In Detail

AML: The Basics

No Updates

 

Chronic Lymphocytic Leukemia: In Detail​ 

CLL: The Basics

No Updates

 

Chronic Myeloid Leukemia: In Detail​ 

CML: The Basics

No Updates

 

<< Previous Page

 


 

Blood Cancer United resources

Find free, specialized guidance and information for every type of blood cancer, request financial support, find emotional support, and connect with other members of the blood cancer community.

We are Blood Cancer United.

Everyone affected by blood cancer—patients, survivors, caregivers, researchers, advocates, fundraisers, everyone—has a story. Share yours.

Emily

B-cell acute lymphoblastic leukemia (B-ALL)

Lana

acute myeloid leukemia (AML)

Katharine

B-cell acute lymphoblastic leukemia (B-ALL)

Joy

acute myeloid leukemia (AML)

Abelina

acute myeloid leukemia (AML)

Twins with T-Cell ALL

Alec and Aden

T-cell acute lymphoblastic leukemia (T-cell ALL)

Aero

B-cell acute lymphoblastic leukemia (B-ALL)

Fast Company Brands That Matter 2022 Logo

Chase

acute lymphoblastic leukemia (ALL)

Myeloma Link logo lock 10.26.22

Judy

chronic myeloid leukemia (CML)

Admin Use Approval Required

Tony

acute lymphoblastic leukemia (ALL)

Holly

diffuse large B-cell lymphoma (DLBCL)

Dawson

acute lymphoblastic leukemia (ALL)

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United. Learn more.